The global genomics market size was estimated at USD 17.2 billion in 2019 and is anticipated to expand at a CAGR of 7.7% over the forecast period. Noninvasive cancer screening-based research is one of the major factors playing a pivotal role in reshaping the genomics industry. Researchers from diverse areas of expertise are engaged in the development and establishment of clinical uses for gene-based liquid biopsy tests.
Liquid biopsy solutions identify cancer-causing DNA mutations thus enabling early detection of cancer. Several companies have begun leveraging on genomics for the development of DNA liquid biopsy tests in order to detect cancer at an early stage. Increasing applications of genomics in medicine have gained attention from military organizations, resulting in a significant increase in the adoption of genetic testing in their healthcare systems. Military practitioners are implementing ‘Carrier Screening for Genetic Conditions’ guidelines, which recommends Spinal Muscular Atrophy (SMA) screening in pregnant women.
Implementation of human genomics studies across public health programs such as population screening and consumer wellness programs are expected to create lucrative opportunities for the market. These programs are primarily targeted at optimizing preventive care for common chronic diseases such as cancer and heart disease.
Traditional genome editing technologies are time-consuming, inefficient, and labor-intensive and have a limited capacity of maintaining pace with the fast-progressing genome modification era. However, the advent of CRISPR/Cas9 nuclease, ZFN, and TALEN is set to address these challenges by facilitating easy and precise genome editing.
Clinical healthcare is being considered as a gateway for introducing new sequencing technologies for U.S. residents. This trend is propelled by healthcare giants focusing on providing medical genomics across clinical patient care delivery. Also, newly developed gene-editing technologies can control and potentially cure specific diseases via the detection of underlying mutations in an individual. Thus, innovations in the medical genomics industry are expected to offer profitable opportunities for the market in the near future.
Functional genomics is expected to be the largest revenue-generating segment by 2027 owing to the generation of a large amounts of sequencing data. The introduction of high-throughput technologies employed in gene and protein studies has contributed to the segment growth. Advancements in the genomics industry range from studying individual genes to complete genomes and proteomes within a comparatively shorter time durations, which is another factor driving the segment growth.
Investigating communication and response in individual targets within the molecular networks has offered useful insights regarding biological functions at a cellular level. Pathway analysis has emerged as a pivotal aspect to strengthen life sciences research along with a fundamental understanding of molecular and cellular biology targeted toward drug development. Thus, the pathway analysis approach is set to gain significant traction post the emergence of personalized therapies and genomics.
The integration of genomics in the field of personalized therapy enables an in-depth analysis of navigating signaling pathways and disease networks. This further aids in addressing challenges associated with the development of therapeutics and genetic assays. Various biological resource types including gene ontology, gene annotation databases, and pathway databases can be effectively employed for pathway-based analysis.
There is an increase in the number of demonstrations pertaining to miniaturized instruments targeted toward genomics applications in recent years. These instruments are designed to offer enhanced specificity, sensitivity, and automated features as compared to conventional instruments.
However, the development of microfabrication technology and integrated microfluidic genomics systems is now aimed at the development of point-of-care devices. Increasing the use of impedimetric detection is one of the promising techniques for the instruments in the market. Moreover, companies such as Formulatrix, Inc. are introducing innovative instruments that help researchers prepare and process samples before subjecting them to analysis.
Increasing adoption of cloud-based solutions for robust and effective management of parallelization along with distribution of input data and user code on a large number of computer nodes is expected to propel the software solutions sector. This is anticipated to further contribute to the segment growth.
Cloud computing offers a very prominent advantage of performing tasks in different parallel computing nodes along with the processors, which results in a significant reduction in waiting time. The integration of cloud computing solutions in processing NGS related data is expected to have a significant impact on genomics market growth.
A steep decline in sequencing costs coupled with technological enhancements in informatics, genetic solutions are now widely used across various sectors ranging from small labs to clinical settings. Key end-use segments consist of pharmaceutical and biotechnology companies, hospitals and clinics, academic and government institutes, clinical and research laboratories, and other end users.
Among these, the pharmaceutical and biotechnology companies segment is expected to dominate the global market throughout the forecast period owing to increasing number of genetic research studies. These are chiefly aimed at the development of efficacious drugs with fewer side effects and improving drug discovery process. This is also attributed to expanding penetration of genomics across diseases associated with immune system, central nervous system, and cardiovascular system.
Moreover, biotechnology companies are effectively employing gene-editing tools to address challenges pertaining to personalized treatment of patients through development of genetically engineered and recombinant products. Other end-users include agriculture research institutes, direct-to-consumer (DTC), and forensic centers. The others segment is anticipated to witness profitable growth owing to significant demand for DTC among consumers, government, and genomics companies.
North America is anticipated to emerge as the dominant region in the market owing to rising patient awareness, substantial investments in research by government organizations, and advanced healthcare infrastructure. Changing regulations for usage and reimbursement are expected to fuel the adoption of genetic tests in this region.
Presence of key players such as Bio-Rad Laboratories, Inc.; Cepheid, Inc.; Agilent Technologies; and Danaher Corporation have also contributed to the revenue generated by this region. Whereas companies such as Illumina, Genomic Health, and Bluebird Bio that is operating at the forefront for revolutionizing the genomics industry, are also headquartered in the U.S. These companies serve as pioneers in the fields of genetic sequencing, genetic diagnostics, and gene therapy respectively.
Asia Pacific is expected to witness the fastest growth in the coming years owing to increasing adoption and awareness for latest genomics technologies in the emerging countries of this region. These technologies are targeted toward detection, treatment, and prognosis of genetic disorders. China is playing a pivotal role in regional market growth by initiatives such as introduction of the Precision Medicine Initiative (PMI) for the use of genomics in healthcare in 2017.
Major players include F. Hoffmann-La Roche Ltd..; Agilent Technologies, Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; 23andMe, Inc.; Illumina, Inc.; Myriad Genetics, Inc.; Foundation Medicine, Inc.; Danaher; Pacific Biosciences; Oxford Nanopore Technologies; and BGI.
In June 2019, BGI partnered with Eluthia, a Germany-based biotechnology company, for the development and commercialization of reproductive genetic tests across Germany. Such alliances are set to intensify the market competition in the near future.
Base year for estimation
Actual estimates/ Historical data
2016 - 2018
2020 - 2027
Revenue in USD Million & CAGR from 2020 to 2027
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, Japan, China, Brazil, and South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2027. For the purpose of this report, Grand View Research has segmented the global genomics market report on the basis of application and technology, deliverables, end use, and region:
Deliverable Outlook (Revenue, USD Million, 2016 - 2027)
Instruments & Software
Consumables & Reagents
Core Genomics Services
Biomarker Translation Services
Application & Technology Outlook (Revenue, USD Million, 2016 - 2027)
Chromatin immunoprecipitation-sequencing (ChIP & ChIP-Seq)
Methylated DNA immunoprecipitation (MeDIP)
High resolution melt (HRM)
Chromatin accessibility assays
Proteomics tools (2-D PAGE; yeast 2-hybrid studies)
End-use Outlook (Revenue, USD Million, 2016 - 2027)
Clinical & Research Laboratories
Academic & Government Institutes
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Other End Users
Regional Outlook (Revenue, USD Million, 2016 - 2027)
Middle East and Africa (MEA)
b. The global Genomics market size was estimated at USD 17.2 billion in 2019 and is expected to exhibit a CAGR of 7.7% during the forecast period.
b. The global Genomics market size is estimated to reach USD 31.1 billion by 2027.
b. Owing to the generation of large amount of sequencing data. Functional Genomics is expected to generate highest revenue by 2027.
b. Asia Pacific is expected to witness the fastest growth over the forecast period owing to the awareness and increase in adoption of latest genomics technologies in the region.
b. Some of the key players are F. Hoffmann-La Roche Ltd..; Agilent Technologies, Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; 23andMe, Inc.; Illumina, Inc.; Myriad Genetics, Inc.; Foundation Medicine, Inc.; Danaher; Pacific Biosciences; Oxford Nanopore Technologies; and BGI.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.